Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06812325 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 321 to 320
    • Primary completion date changed from estimate of Apr 2026 to Apr 22, 2026
    v11
  2. Secondary endpoints revised (2)v10
  3. Enrollment target: estimated 284 to confirmed 321
    • Study sites: 48 to 64
    • Primary completion date: Oct 2026 to Apr 2026
    • Eligibility criteria expanded, about 16 words
    v9
  4. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 47 to 48
    • Primary completion date: Sep 2026 to Oct 2026
    • Study completion date: Dec 2026 to Oct 2026
    v8
  5. Study sites: 18 to 47v7
Show 5 earlier versionsHide 5 earlier versions
  1. Re-verified, no change to tracked fieldsv6
  2. Study sites: 10 to 18v5
  3. Study sites: 1 to 10v4
  4. Study site revisedv3
  5. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Feb 2025 to Feb 3, 2025
    • Eligibility criteria shortened, about 183 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study description expanded, about 59 words
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).
Trial Details
NCT Number NCT06812325
Lead Sponsor Viridian Therapeutics, Inc.
Conditions
(from sponsor)		 Thyroid Eye Disease (TED)
Related terms Graves Ophthalmopathy
Enrollment 320 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov